Alcon bags CE mark for preloaded intraocular lens delivery system

Alcon scored a CE mark for its Clareon intraocular lens in May and hopes to gain FDA approval for the device next year.

Novartis’ Alcon earned a CE mark for its automated, disposable, preloaded intraocular lens delivery system. The company is introducing the device, dubbed AutonoMe, alongside its next-gen Clareon intraocular lens (IOL).

The AutonoMe device uses a carbon dioxide-powered delivery mechanism to insert an IOL during cataract surgery, Alcon said in a statement.

"Comfort and efficiency during the cataract surgery are key to achieving better outcomes. This new device is expected to improve the procedure and ultimately to reduce surgical time," said Rudolph Nuijts of University of Maastricht in the Netherlands in the statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Alcon will debut the AutonoMe device and the Clareon IOL at the European Society of Cataract and Refractive Surgeons Congress next week. The company expects to roll out the product duo in the EU in early 2018. Novartis aims to get Clareon past the FDA in 2019.

Cataract surgery, which involves removing the cataract and implanting an IOL, is required when a patient’s cataract interferes with his or her daily activities, or if it prevents the patient from receiving treatment for a separate eye condition, according to the National Eye Institute.

Alcon—the subject of a turnaround plan announced early last year to remedy its slumping sales—gave Novartis an unexpected boost in the second quarter this year with a 3% increase to $1.5 billion.

Suggested Articles

The Rady Children’s Institute for Genomic Medicine tapped Deloitte to help develop a network of flying drones to deliver genetic testing specimens.

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.